Arcturus' COVID-19 Booster Shows Durability Against Omicron Variants

  • Arcturus Therapeutics Holdings Inc ARCT announced updated data from its ongoing ARCT-154 booster clinical trial. 
  • The new results demonstrate a broad neutralizing antibody response against omicron variants of concern, including BA.5, lasting up to at least six months after administering a low-dose (5 mcg) ARCT-154 booster.
  • “Our next generation low-dose self-amplifying (STARR™) mRNA technology continues to differentiate itself from conventional mRNA vaccine technology,” said Joseph Payne, President & CEO.
  • “Further validation of the breadth and duration for the immune responses to ARCT-154 are planned in upcoming pivotal clinical trial activities,” he added.
  • Related: Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial.
  • After one month and three months, neutralizing antibody responses to Omicron BA.5 were 33- and 20-fold elevated over pre-boost responses, respectively. 
  • After six months, neutralizing antibody responses to omicron BA.1, BA.2, and BA.5 ranged from 22-52 fold, 25-55 fold and 9-24 fold elevated over pre-boost responses, respectively.
  • These data show sustained neutralizing responses to antigenically distinct variants of concern, including omicron BA.5, for at least six months after vaccination.
  • Price Action: ARCT shares are down 6.79% at $19.05 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!